Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week extension safety study of CSJ117 in adults with asthma (Japan)
jRCT2031210301Completed
- Sponsor
- Novartis
- Start
- Sep 2021
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in asthma comparing CSJ117 arm with Placebo arm (2 arms). Started Sep 2021; status: completed.
02
Drugs
ecleralimab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031210301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210301.